LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-302 in Combination with Anti-PD-1 Antibody

2025-03-27
Share:

SHANGHAI, March 27^th, 2025 – LaNova Medicines Ltd. announced that its core pipeline asset, LM-302, an anti-Claudin 18.2 ADC, has been granted to conduct a phase 2 study in combination with anti-PD-1 antibody.

Previous

LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-108 in Combination with other Anti-Cancer Agents
Next

CDE Granted LM-108 Breakthrough Therapy Designation for MSI-H/dMMR Solid Tumors